KalVista Pharmaceuticals
Dec 16, 2024 · KalVista is advancing science to empower everyday lives with innovative oral medicines. KalVista’s mission begins with hereditary angioedema, HAE. Patients & Caregivers
About Us - KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company discovering, developing and commercializing oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system.
Pipeline - KalVista Pharmaceuticals
KalVista is building a pipeline of novel oral, small molecule protease inhibitors through preclinical and clinical development as potential best-in-class treatments for a range of diseases, beginning with hereditary angioedema (HAE).
KalVista Pharmaceuticals, Inc. (KALV) Stock Price, News, Quote ...
Find the latest KalVista Pharmaceuticals, Inc. (KALV) stock quote, history, news and other vital information to help you with your stock trading and investing.
KalVista Pharmaceuticals, Inc. (KALV) - Stock Analysis
5 days ago · Get a real-time KalVista Pharmaceuticals, Inc. (KALV) stock price quote with breaking news, financials, statistics, charts and more.
KALV Stock Price | KalVista Pharmaceuticals Inc. Stock Quote …
6 days ago · KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases...
KalVista Announces FDA Acceptance of New Drug Application for ...
Sep 3, 2024 · KalVista announced positive phase 3 data from the KONFIDENT trial for its oral, on-demand therapy, sebetralstat for HAE in February 2024. The Company’s NDA for sebetralstat has been accepted by the FDA with a PDUFA goal date of June 17, 2025 .
KalVista Pharmaceuticals Provides Operational Update and Fiscal …
Jul 11, 2024 · KalVista Pharmaceuticals, Inc. is a global pharmaceutical company focused on the development and delivery of oral medicines for diseases with significant unmet need. KalVista announced positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024 and submitted an NDA with the FDA in June 2024 .
KalVista Announces Orphan Drug Designation and NDA
2 days ago · KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant ...
KalVista Announces Orphan Drug Designation and NDA …
1 day ago · CAMBRIDGE, Mass. & SALISBURY, England, January 21, 2025--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted ...
- Some results have been removed